Moretti August J
Known title: Chief Financial OfficerCIK: 0001344412
Associated companies
Transaction History
| FDMT | ▲ Buy | Option Exercise | 3,000 | $28K | 5/15/2023 | View on chart |
| FDMT | ▲ Buy | Option Exercise | 3,000 | $28K | 12/21/2022 | View on chart |
| FDMT | ▲ Buy | Option Exercise | 3,000 | $28K | 5/15/2023 | View on chart |
| FDMT | ▲ Buy | Option Exercise | 3,000 | $28K | 12/21/2022 | View on chart |
We use analytics to understand how market-wall is used. No personal data is sold.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 25, 2026
FDMT listed in Benzinga pre-market movers
4D Molecular Therapeutics was mentioned in a Benzinga report on stocks moving lower in Friday’s pre-market session. The article grouped FDMT with other companies like Scholastic and Zscaler, noting a generally downbeat tone among legacy education and other large-cap names. This indicates the stock was part of a broader market movement rather than reacting to a company-specific announcement.
FDMT listed in Benzinga pre-market movers. 4D Molecular Therapeutics was mentioned in a Benzinga report on stocks moving lower in Friday’s pre-market session. The article grouped FDMT with other companies like Scholastic and Zscaler, noting a generally downbeat tone among legacy education and other large-cap names. This indicates the stock was part of a broader market movement rather than reacting to a company-specific announcement.